Press release
Sickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsight
Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034
DelveInsight's "Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the sickle cell disease treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and sickle cell disease market forecasts through 2034, providing crucial insights for stakeholders in the sickle cell disease therapeutic area.
According to DelveInsight's analysis, the sickle cell disease treatment market is projected to grow substantially during the forecast period (2025-2034), driven by enhanced understanding of disease mechanisms, gene therapy innovations, and breakthrough CRISPR-based treatment approaches.
The sickle cell disease market was valued at approximately USD 650 million in 2023 across the 6MM countries and is expected to increase throughout the forecast period. The United States accounted for the highest market share in 2023, representing approximately USD 603 million, or nearly 92% of the total market share compared to EU4 and the UK. Among EU4 and the UK, France accounted for the largest market share, while Spain accounted for the smallest share.
Download the Sickle Cell Disease Market report to understand which factors are driving the Sickle Cell Disease therapeutic market @ Sickle Cell Disease Market Trends [https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The DelveInsight's report further categorizes the sickle cell disease patient population into several main groups for epidemiological analysis. In the US, among the sickle cell disease type-specific prevalent cases, sickle cell anemia (hemoglobin S/S or hemoglobin S/BO-thalassemia) was identified as the major subtype of sickle cell disease. The report provides comprehensive segmentation, including total prevalent cases of sickle cell disease trait, total prevalent cases of sickle cell disease, diagnosed cases, age-specific prevalent cases, and type-specific prevalence across all studied markets.
Discover evolving trends in the Sickle Cell Disease patient pool forecasts @ Sickle Cell Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The sickle cell disease treatment landscape has been revolutionized by recent FDA approvals of breakthrough gene therapies. A significant milestone occurred in December 2023 when CASGEVY (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, received FDA approval as the first CRISPR/Cas9 genome-edited cell therapy for treating sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises. Additionally, LYFGENIA (Lovo-cel) from bluebird bio received approval, marking another major advancement in gene therapy approaches for this devastating genetic disorder.
The current treatment paradigm includes several FDA-approved therapies addressing different aspects of sickle cell disease management. ENDARI (L-glutamine) from Emmaus Life Sciences provides oral pharmaceutical-grade L-glutamine to reduce severe complications in adult and pediatric patients aged 5 and older. OXBRYTA (voxelotor) became the first-in-class oral therapy targeting the underlying cause of sickle cell disease with convenient oral administration, while ADAKVEO (crizanlizumab) offers targeted therapy to reduce vaso-occlusive crises.
According to the DelveInsight report, the sickle cell disease therapies pipeline demonstrates robust potential with several novel treatments in late-stage development. Agios Pharmaceuticals' Mitapivat, a first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme, has successfully met its primary endpoint in the Phase II portion of the global RISE UP study, demonstrating hemoglobin response for patients in both the 50 mg and 100 mg twice daily mitapivat arms. Pfizer's Inclacumab (PF-07940370) is currently in Phase III development following the company's acquisition of Global Blood Therapeutics, while Novo Nordisk's etavopivat and other pipeline candidates including EDIT-301 (Reni-cel) and Osivelotor (GBT-601) are expected to be major contributors to market growth.
Recent developments highlight the dynamic nature of the sickle cell disease treatment landscape. In June 2025, Beam Therapeutics' BEAM-101 received FDA orphan drug designation for SCD. BEAM-101 is a precision genetic medicine currently in a Phase 1/2 clinical trial (BEACON) for patients with severe sickle cell disease. Sanofi's Rilzabrutinib also received FDA orphan drug designation for SCD in the same month. Rilzabrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor targeting the reduction of vaso-occlusive crises through immune modulation, demonstrating continued regulatory support for innovative therapeutic approaches.
Furthermore, in March 2025, the FLT1 gene is identified by a group of scientists as a potential new target for gene editing in SCD. Editing FLT1 could increase fetal hemoglobin, which is associated with improved outcomes for sickle cell disease patients.
Discover recent advancements in the Sickle Cell Disease treatment landscape @ Sickle Cell Disease Recent Developments [https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The sickle cell disease treatment market remains highly competitive, with major pharmaceutical companies and emerging biotechnology firms advancing various therapeutic approaches. Key players include Global Blood Therapeutics (acquired by Pfizer), Vertex Pharmaceuticals collaborating with CRISPR Therapeutics, Agios Pharmaceuticals, Editas Medicine, Forma Therapeutics (partnered with Novo Nordisk), Bausch Health, Bluebird Bio, and Emmaus Life Sciences, all contributing to a diverse pipeline spanning small molecules, gene therapies, and cell-based treatments.
Looking ahead, the sickle cell disease market is expected to witness continued innovation driven by advances in gene editing technologies, improved understanding of disease pathophysiology, and personalized medicine approaches. While significant progress has been made with the approval of gene therapies, challenges remain in addressing treatment accessibility, affordability, and managing the complex logistics of cell-based therapies. The market outlook indicates positive growth potential, with pipeline candidates such as Etavopivat, Inclacumab, Reni-cel, and Osivelotor expected to drive market expansion during the forecast period.
DelveInsight's analysis underscores the substantial opportunities that remain for developing more accessible, cost-effective treatment options that can provide durable clinical benefits and improved quality of life for sickle cell disease patients worldwide. As gene therapy technologies mature and novel therapeutic mechanisms are explored, the sickle cell disease market is positioned for remarkable transformation and expansion.
Table of Contents
1. Key Insights
2. Report Introduction
3. Sickle Cell Disease Market Overview at a Glance
4. Sickle Cell Disease Market: Future Perspective
5. Executive Summary of Sickle Cell Disease
6. Key Events
7. Sickle Cell Disease Background and Overview
8. Sickle Cell Disease Market Epidemiology and Patient Population
9. Sickle Cell Disease Patient Journey
10. Sickle Cell Disease Marketed Drugs
11. Sickle Cell Disease Emerging Drugs
12. Sickle Cell Disease: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Sickle Cell Disease Market Unmet Needs
15. SWOT Analysis
16. Reimbursement and Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Sickle Cell Disease Pipeline Insight [https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Sickle Cell Disease pipeline insight provides comprehensive insights about the Sickle Cell Disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Sickle Cell Disease companies, including Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc., GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, and Base Therapeutics, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sickle-cell-disease-treatment-market-set-for-robust-growth-through-2034-driven-by-recent-clinical-pipeline-developments-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsight here
News-ID: 4088641 • Views: …
More Releases from ABNewswire
NOVITEC Pushes the Ferrari Daytona SP3 to 868 HP with Fine Gold-Coated Exhaust S …
The German tuner also fitted custom Vossen forged NF10 wheels in 20- and 21-inch diameters and offers bespoke interior options for the limited-edition Ferrari icon.
Image: https://www.abnewswire.com/upload/2026/02/82ce418bb38a091c38f5c71e89ceff7a.jpg
NOVITEC [https://www.novitec.com/], a reputable specialist for Ferrari customization, has released a comprehensive performance and styling package for the Ferrari Daytona SP3 - one of the rarest automobiles produced by the Maranello manufacturer and part of Ferrari's exclusive Icona series. The package raises peak output to…
Quality Assurance Autos Leads the Industry in Used Car Sales
Quality Assurance Autos leads salvage car sales by offering reliable vehicles, simple buying processes, and global access. QA Autos helps buyers find affordable salvage and used vehicles with clear listings and dependable support worldwide.
Quality Assurance Autos continues to stand out as a trusted name in the salvage or used vehicle market. With years of experience and a clear focus on customer satisfaction, the platform has built a strong reputation among…
Closing the Connectivity Gap: How DishNinjas Is Serving the Rural Southeast
Image: https://www.abnewswire.com/upload/2026/02/6bfcc7cd0799e6315ba51c0f1a41bfe4.jpg
The demand for high-speed, reliable internet has shifted from a luxury to a necessity, yet many rural and underserved areas across the Southeast continue to face infrastructure limitations. While Starlink provides powerful satellite technology, professional installation is often the difference between average performance and optimal results.
We spoke with Andrew Zdunich, Field Operations Manager at DishNinjas, about the company's rapid expansion and commitment to delivering dependable connectivity.
Q: With the recent…
Mindsec Shares New Data Residency Report: Why 40% of Canadian CISOs Are Repatria …
Mindsec, a Canada-based security compliance automation platform, has released a new Data Residency Report highlighting a significant shift in compliance data strategy among Canadian organizations. According to the report, approximately 40% of Canadian Chief Information Security Officers (CISOs) are actively repatriating compliance data from US-based vendors to Canadian-hosted environments.
The findings reflect growing concerns around cross-border data exposure, regulatory complexity, and geopolitical uncertainty. As compliance requirements expand across frameworks such as…
More Releases for Sickle
Sickle Cell Disease Treatment Market - Improving Quality of Life: Pioneering Sic …
Newark, New Castle, USA: The "Sickle Cell Disease Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Sickle Cell Disease Treatment Market: https://www.growthplusreports.com/report/sickle-cell-disease-treatment-market/7808
This latest report researches the…
Sickle Cell Disease Treatment Market - Breaking the Chains of Sickle Cell: Pione …
Newark, New Castle, USA - new report, titled Sickle Cell Disease Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Sickle Cell Disease Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Sickle Cell Disease Treatment market. The report offers…
Global Sickle Cell Disease Treatment Market 2023: Sickle Cell Anaemia Anticipate …
The sickle cell disease treatment market is a segment of the broader pharmaceutical industry that is focused on developing treatments for sickle cell disease, a genetic disorder that affects the red blood cells. In 2022, the sickle cell disease treatment market is expected to continue to grow, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to be worth billions of…
Global Sickle Cell Disease Treatment Market 2023: Sickle Cell Anaemia Anticipate …
The sickle cell disease treatment market refers to the segment of the healthcare industry that produces and markets treatments for sickle cell disease (SCD), a genetic disorder that affects the production of hemoglobin in red blood cells. SCD can cause various complications, including pain, infections, and organ damage, and there is currently no cure for the disease. However, various treatments are available that can help manage the symptoms and improve…
Global Sickle Cell Disease Treatment Market 2023: Sickle Cell Anaemia Anticipate …
The sickle cell disease treatment market refers to the segment of the pharmaceuticals industry that deals with the production and sales of treatments for sickle cell disease. Sickle cell disease is a genetic blood disorder that causes red blood cells to become misshapen and form a sickle shape. This can lead to a range of complications, including anemia, chronic pain, and increased risk of infections.
The market for sickle cell disease…
Global Sickle Cell Disease Treatment Market 2023: Sickle Cell Anaemia Anticipate …
The Sickle Cell Disease Treatment Market is an emerging segment in the healthcare industry. This debilitating disorder affects millions of people around the world, with no known cure available. However, recent advances in research have improved the treatment options for those suffering from sickle cell disease. The Sickle Cell Disease Treatment Market is expected to experience significant growth over the coming years as treatments become more effective and accessible. Several…
